You are here

PCSK9 inhibitors

Sanofi and Amgen, eyeing boost for PCSK9 use, tout benefits for diabetes patients

Sanofi and Amgen, eyeing boost for PCSK9 use, tout benefits for diabetes patients

Fierce Pharma

PCSK9 inhibitors

Flag link:

Insurers, doctors battle over new heart disease drugs

Insurers, doctors battle over new heart disease drugs

CNBC

cardiovascular disease

PCSK9 inhibitors

Flag link:

In cost debate, Amgen stands by Repatha's value

In cost debate, Amgen stands by Repatha's value

BioPharma Dive

PCSK9 inhibitors

Flag link:

ADA preview: 5 things to watch in diabetes

ADA preview: 5 things to watch in diabetes

BioPharma Dive

Boehringer Ingelheim

PCSK9 inhibitors

Amgen Regeneron

Flag link:

Lilly, Pfizer, et al. back Sanofi and Regeneron in PCSK9 patent appeal. AbbVie doesn't

Lilly, Pfizer, et al. back Sanofi and Regeneron in PCSK9 patent appeal. AbbVie doesn't

Fierce Pharma

PCSK9 inhibitors

Flag link:

Amgen Identifies Issue with Patient Access to PCSK9 Inhibitor

Amgen Identifies Issue with Patient Access to PCSK9 Inhibitor

Xtalks

PCSK9 inhibitors

Flag link:

When it comes to PCSK9s, payers resisted — and sales flopped

When it comes to PCSK9s, payers resisted — and sales flopped

Medical Marketing and Media

PCSK9 inhibitors

Flag link:

Sanofi, Regeneron one step closer to owing PCSK9 royalties as judge upholds Amgen patent ruling

Sanofi, Regeneron one step closer to owing PCSK9 royalties as judge upholds Amgen patent ruling

Fierce Pharma

PCSK9 inhibitors

Flag link:

No early success for Regeneron, Sanofi in PhIII outcomes study for PCSK9 drug Praluent

No early success for Regeneron, Sanofi in PhIII outcomes study for PCSK9 drug Praluent

Endpoints

PCSK9 inhibitors

Flag link:

Data in hand, The Medicines Co. speeds PCSK9 plans

Data in hand, The Medicines Co. speeds PCSK9 plans

BioPharma Dive

The Medicines Company

PCSK9 inhibitors

Flag link:

Death Of Pfizer Heart Drug Shows The Challenges Of CV R&D And Why Companies Are Bowing Out

Death Of Pfizer Heart Drug Shows The Challenges Of CV R&D And Why Companies Are Bowing Out

Forbes

PCSK9 inhibitors

Flag link:

Pfizer Discontinues Development of PCSK9 Inhibitor

Pfizer Discontinues Development of PCSK9 Inhibitor

Xtalks

PCSK9 inhibitors

Flag link:

These pricey cholesterol drugs aren’t selling. And that has the biotech industry sweating

These pricey cholesterol drugs aren’t selling. And that has the biotech industry sweating

Stat

PCSK9 inhibitors

Flag link:

Despite Promising Early Data, The New Cholesterol Lowering Drug - PCSK9si - Has Significant Hurdles

Despite Promising Early Data, The New Cholesterol Lowering Drug - PCSK9si - Has Significant Hurdles

Forbes

PCSK9 inhibitors

The Medicines Company

Flag link:

Amgen, Sanofi and Regeneron trot out new PCSK9 data at European heart meeting

Amgen, Sanofi and Regeneron trot out new PCSK9 data at European heart meeting

Fierce Pharma

PCSK9 inhibitors

Flag link:

These Next-Generation Cholesterol Drugs Could Raise U.S. Healthcare Costs by $119 Billion a Year

These Next-Generation Cholesterol Drugs Could Raise U.S. Healthcare Costs by $119 Billion a Year

Motley Fool

PCSK9 inhibitors

Flag link:

Amgen refutes 'flawed' cholesterol study

Amgen refutes 'flawed' cholesterol study

BioPharma Dive

PCSK9 inhibitors

Flag link:

Are PCSK9 meds worth the cost? Only if Amgen, Sanofi and Regeneron slash prices by two-thirds: JAMA

Are PCSK9 meds worth the cost? Only if Amgen, Sanofi and Regeneron slash prices by two-thirds: JAMA

Fierce Pharma

PCSK9 inhibitors

Flag link:

Amgen touts new dosing option for underperforming cholesterol drug

Amgen touts new dosing option for underperforming cholesterol drug

BioPharma Dive

PCSK9 inhibitors

Flag link:

FDA Approves First And Only Single Monthly Injection For A PCSK9 Inhibitor

FDA Approves First And Only Single Monthly Injection For A PCSK9 Inhibitor

Yahoo

Repatha Pushtronex

PCSK9 inhibitors

Flag link: